Cargando…

Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline

Cetrorelix, a luteinising hormone-releasing hormone (LHRH) analogue, has been shown to limit growth of the human androgen-independent prostate cell line DU-145, although other inhibitory actions may also be affected. Both growth and invasion of DU-145 cells are linked to autocrine epidermal growth f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yates, C, Wells, A, Turner, T
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2005
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361841/ https://www.ncbi.nlm.nih.gov/pubmed/15655536 http://dx.doi.org/10.1038/sj.bjc.6602350

Ejemplares similares

Cellular changes in boric acid-treated DU-145 prostate cancer cells
por: Barranco, W T, et al.
Publicado: (2006)

Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer
por: Tam, L, et al.
Publicado: (2007)

The functional significance of microRNA-145 in prostate cancer
por: Zaman, M S, et al.
Publicado: (2010)

Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630.
por: Plowman, P. N., et al.
Publicado: (1986)

Measuring luteinising hormone pulsatility with a robotic aptamer-enabled electrochemical reader
por: Liang, Shaolin, et al.
Publicado: (2019)

Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma
por: Kobayashi, M, et al.
Publicado: (2012)

Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology
por: Ursin, G, et al.
Publicado: (2005)

Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients
por: McCall, P, et al.
Publicado: (2008)

Hypothalamic effects of progesterone on regulation of the pulsatile and surge release of luteinising hormone in female rats
por: He, Wen, et al.
Publicado: (2017)

NF-κB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation
por: Van Laere, S J, et al.
Publicado: (2007)

The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer
por: Villadsen, S B, et al.
Publicado: (2012)

MicroRNA-145 inhibits tumour growth and metastasis in colorectal cancer by targeting fascin-1
por: Feng, Y, et al.
Publicado: (2014)

Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients
por: Innes, H E, et al.
Publicado: (2006)

Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer
por: Armstrong, K, et al.
Publicado: (2011)

Effects of platelet-activating factor and its differential regulation by androgens and steroid hormones in prostate cancers
por: Xu, B, et al.
Publicado: (2013)

Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects.
por: Crighton, I. L., et al.
Publicado: (1989)

Long-term morphological and hormonal follow-up in a single unit on 115 patients with adrenal incidentalomas
por: Bernini, G P, et al.
Publicado: (2005)

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer
por: Ålgars, A, et al.
Publicado: (2011)

The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients
por: Avgeris, M, et al.
Publicado: (2013)

Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status
por: Rego, R L, et al.
Publicado: (2010)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

A review of luteinising hormone and human chorionic gonadotropin when used in assisted reproductive technology
por: Ezcurra, Diego, et al.
Publicado: (2014)

Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats.
por: Bokser, L., et al.
Publicado: (1990)

miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer
por: Chiyomaru, T, et al.
Publicado: (2010)

Identification of a hypoxia-regulated miRNA signature in bladder cancer and a role for miR-145 in hypoxia-dependent apoptosis
por: Blick, C, et al.
Publicado: (2015)

Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma
por: Engelsen, I B, et al.
Publicado: (2008)

EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?
por: Paliga, A, et al.
Publicado: (2012)

Circulating levels of testosterone, 17 beta-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients.
por: Secreto, G., et al.
Publicado: (1983)

EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target
por: Iida, K, et al.
Publicado: (2011)

Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer
por: Koike, H, et al.
Publicado: (2005)

The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone
por: Campbell, Esther J, et al.
Publicado: (2016)

Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options
por: Scartozzi, M, et al.
Publicado: (2007)

Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers
por: Harlé, A, et al.
Publicado: (2015)

The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions
por: Terry, G, et al.
Publicado: (2007)

Targeting EGFR and PI3K pathways in ovarian cancer
por: Glaysher, S, et al.
Publicado: (2013)

Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10
por: Modjtahedi, H, et al.
Publicado: (2012)

Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin
por: Yates, C C, et al.
Publicado: (2007)

Overexpression and altered glycosylation of MUC1 in malignant mesothelioma
por: Creaney, J, et al.
Publicado: (2008)

Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
por: Miyamoto, M, et al.
Publicado: (2011)

DKC1 overexpression associated with prostate cancer progression
por: Sieron, P, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ckhhkl6riqcgu1fcj58gbiq1ht